Akari Therapeutics Plc (AKTX) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
22 BOSTON WHARF ROAD BOSTON, MA 02210 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 68,920 | 6,216 | |||
| Cash and cash equivalents | 68,920 | 6,216 | |||
| Restricted cash and investments | 142 | ||||
| Receivables | 10 | ||||
| Prepaid expense | |||||
| Other current assets | |||||
| Other undisclosed current assets | 728 | 73 | |||
| Total current assets: | 69,658 | 6,431 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 41 | 49 | |||
| Intangible assets, net (including goodwill) | 52 | ||||
| Intangible assets, net (excluding goodwill) | 52 | ||||
| Restricted cash and investments | 142 | ||||
| Total noncurrent assets: | 235 | 49 | |||
| TOTAL ASSETS: | 69,894 | 6,480 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,729 | 1,715 | |||
| Employee-related liabilities | ✕ | 4 | |||
| Accounts payable | 4,321 | 1,359 | |||
| Accrued liabilities | 408 | 352 | |||
| Other liabilities | |||||
| Due to related parties | ✕ | 118 | |||
| Other undisclosed current liabilities | 16,396 | (474) | |||
| Total current liabilities: | 21,125 | 1,359 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 33 | ||||
| Other liabilities | 33 | ||||
| Other undisclosed noncurrent liabilities | 49 | 235 | |||
| Total noncurrent liabilities: | 49 | 268 | |||
| Other undisclosed liabilities | |||||
| Total liabilities: | 21,174 | 1,627 | |||
| Equity | |||||
| Equity, attributable to parent, including: | 48,720 | 4,853 | |||
| Common stock | 18,341 | 927 | |||
| Additional paid in capital | 87,019 | 34,116 | |||
| Accumulated other comprehensive income (loss) | 156 | ||||
| Accumulated deficit | (56,797) | (30,190) | |||
| Other undisclosed equity, attributable to parent | |||||
| Total equity: | 48,720 | 4,853 | |||
| TOTAL LIABILITIES AND EQUITY: | 69,894 | 6,480 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|
| Revenues (Financial Services Revenue) | 549 | |||
| Cost of revenue (Financial Services Costs) | (22,973) | |||
| Gross profit: | (22,973) | 549 | ||
| Operating expenses | (30,585) | (10,177) | ||
| Other undisclosed operating income (loss) | 22,973 | (549) | ||
| Operating loss: | (30,585) | (10,177) | ||
| Nonoperating income (expense) | (14,733) | 529 | ||
| Investment income, nonoperating | 21 | |||
| Gain (loss), foreign currency transaction, before tax | (91) | |||
| Other nonoperating income (expense) | 529 | |||
| Interest and debt expense | (3,054) | |||
| Loss from continuing operations before equity method investments, income taxes: | (48,371) | (9,648) | ||
| Other undisclosed income from continuing operations before income taxes | 3,054 | |||
| Loss from continuing operations: | (45,318) | (9,648) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (45,318) | (9,648) | |
| Net loss: | (45,318) | (9,648) | ||
| Other undisclosed net loss attributable to parent | ||||
| Net loss available to common stockholders, diluted: | (45,318) | (9,648) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|
| Net loss: | (45,318) | (9,648) | ||
| Other comprehensive loss | ||||
| Comprehensive loss: | (45,318) | (9,648) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 110 | |||
| Comprehensive loss, net of tax, attributable to parent: | (45,207) | (9,648) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.